Archives of Clinical Infectious Diseases

Published by: Kowsar

The Follow-up of 360 Patients with Pulmonary Tuberculosis After 2 Months Treatment With Anti-tubercular Agents in Iran

Marzieh Kazerani 1 , * , Maryam Kazerani 2 , Kiarash Ashrafzadeh 1 , Shamim Rahiman 3 , Mahdi Mottaghy 4 and Amin Samihi 5
Authors Information
1 Department of Infectious Disease, Islamic Azad University of Mashhad, Mashhad, IR Iran
2 Department of Medical Library and Information Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Medical Student, Islamic Azad University of Mashhad, Mashhad, IR Iran
4 Medical Student, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 MD-MPH, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: August 2018, 13 (4); e62132
  • Published Online: July 31, 2017
  • Article Type: Research Article
  • Received: April 13, 2016
  • Revised: May 14, 2017
  • Accepted: May 14, 2017
  • DOI: 10.5812/archcid.62132

To Cite: Kazerani M, Kazerani M, Ashrafzadeh K, Rahiman S, Mottaghy M, et al. The Follow-up of 360 Patients with Pulmonary Tuberculosis After 2 Months Treatment With Anti-tubercular Agents in Iran, Arch Clin Infect Dis. 2018 ; 13(4):e62132. doi: 10.5812/archcid.62132.

Copyright © 2017, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. WHO. Available from:"> 2016. Global tuberculosis report.
  • 2. Raviglione MC. Tuberculosis - The Essentials fourth ed. Geneva; 2009.
  • 3. Bennett JE, Dolin R, Blaser MJ. Principles and practice of infectious diseases. Elsevier Health Sciences; 2014.
  • 4. Majdzadeh R, Rahmani K, Nasehi M. What Is the Share of the Country's Researches in Iran's National Tuberculosis Guideline? Iran J Public Health. 2013;42(12):1405-13. [PubMed: 26060642].
  • 5. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson L. Harrison’s principles of internal medicine. 11th. McGraw-Hill Book Company, NY; 2001.
  • 6. Azadi D, Shojaei H. The role of the laboratory in the diagnosis of tuberculosis. Iran J Med Microbiol. 2016;10(2):1-15.
  • 7. Zabeth HR. Landmarks of Mashhad. 1999.
  • 8. Pfyffer GE. Mycobacterium: general characteristics, laboratory detection, and staining procedures. Manual of Clinical Microbiology, Eleventh Edition. American Society of Microbiology; 2015. p. 536-69.
  • 9. Choi R, Jeong BH, Koh WJ, Lee SY. Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations. Ann Lab Med. 2017;37(2):97-107. doi: 10.3343/alm.2017.37.2.97. [PubMed: 28028995].
  • 10. Fonua L, Bissell K, Vivili P, Gounder S, Hill PC. Sputum smear microscopy referral rates and turnaround time in the Tonga Islands. Public Health Action. 2014;4(Suppl 1):S29-33. doi: 10.5588/pha.13.0087. [PubMed: 26477284].
  • 11. Nasehi MM, Moosazadeh M, Amiresmaeili MR, Parsaee MR, Nezammahalleh A. The epidemiology of factors associated with screening and treatment outcomes of patients with smear positive pulmonary tuberculosis: a population-based study. J Mazandaran Univ Med Sci. 2012;21(1):9-18.
  • 12. Dembele SM, Ouedraogo HZ, Combary A, Saleri N, Macq J, Dujardin B. Conversion rate at two-month follow-up of smear-positive tuberculosis patients in Burkina Faso. Int J Tuberc Lung Dis. 2007;11(12):1339-44. [PubMed: 18034956].
  • 13. Manalebh A, Demissie M, Mekonnen D, Abera B. The quality of sputum smear microscopy in public-private mix directly observed treatment laboratories in West Amhara region, Ethiopia. PLoS One. 2015;10(4). e0123749. doi: 10.1371/journal.pone.0123749. [PubMed: 25849516].
  • 14. Bini EI, Mata Espinosa D, Marquina Castillo B, Barrios Payan J, Colucci D, Cruz AF, et al. The influence of sex steroid hormones in the immunopathology of experimental pulmonary tuberculosis. PLoS One. 2014;9(4). e93831. doi: 10.1371/journal.pone.0093831. [PubMed: 24722144].
  • 15. Boushab B, Savadogo M, Sow M. Prevalence of smear-positive pulmonary tuberculosis in Aioun hospital (Hodh El Garbi). Revue de pneumologie clinique. 2016;72(4):243-7.
  • 16. Berezovskii BA, Salobai R, Marchak VV, Popova ,I, Zakopailo GG, Kucher VA, et al. [Factors affecting the treatment results with pulmonary tuberculosis patients]. Vrach Delo. 1991;(12):46-7. [PubMed: 1792770].
  • 17. Unsematham S, Kateruttanakul P. Factors predicting sputum smear conversion and treatment outcomes in new smear-positive pulmonary tuberculosis. J Med Assoc Thailand Chotmaihet thangphaet. 2013;96(6):644-9.
  • 18. Nasiri MJ, Rezaei F, Zamani S, Darban-Sarokhalil D, Fooladi AAI, Shojaei H, et al. Drug resistance pattern of Mycobacterium tuberculosis isolates from patients of five provinces of Iran. Asian Pac J Trop Med. 2014;7(3):193-6. doi: 10.1016/s1995-7645(14)60019-5.
  • 19. Soudbakhsh AR, Ahmadinejad Z, Sistanizadeh M. Sputum Conversion Among Patients With Smear Positive Pulmonary Tuberculosis. Tehran Univ Med JTUMS Pub. 2003;61(1):47-56.
  • 20. Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC, Tami G. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology. 2009;14(7):1012-9. doi: 10.1111/j.1440-1843.2009.01598.x. [PubMed: 19659516].
  • 21. Rathman G, Sillah J, Hill PC, Murray JF, Adegbola R, Corrah T, et al. Clinical and radiological presentation of 340 adults with smear-positive tuberculosis in The Gambia. Int J Tuberc Lung Dis. 2003;7(10):942-7. [PubMed: 14552563].
  • 22. Pajankar S, Khandekar R, Al Amri MA, Al Lawati MR. Factors influencing sputum smear conversion at one and two months of tuberculosis treatment. Oman Med J. 2008;23(4):263.
  • 23. Daley P, Michael JS, S K, Latha A, Mathai D, John KR, et al. A pilot study of short-duration sputum pretreatment procedures for optimizing smear microscopy for tuberculosis. PLoS One. 2009;4(5). e5626. doi: 10.1371/journal.pone.0005626. [PubMed: 19461963].
  • 24. Kurt AO, Sasmaz T, Bugdayci R, Oner S, Yapici G, Ozdemir O. A five year retrospective surveillance; monitoring and evaluation for the regional tuberculosis control programme in Mersin, Turkey, 2004-2008. Cent Eur J Public Health. 2012;20(2):144-9. [PubMed: 22966741].
  • 25. Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ, et al. Smoking and 2-month culture conversion during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2013;17(2):225-8. doi: 10.5588/ijtld.12.0426. [PubMed: 23317958].
  • 26. Farazi A, Shafaat O, Sofian M, Kahbazi M. Arginine adjunctive therapy in active tuberculosis. Tuberculosis Res Treat. 2015;2015.
  • 27. Khandelwal D, Gupta N, Mukherjee A, Lodha R, Singh V, Grewal HM, et al. Vitamin D levels in Indian children with intrathoracic tuberculosis. Indian J Med Res. 2014;140(4):531-7. [PubMed: 25488448].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments